Brief: Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models
03/03/2026 13:48
March 3 (Reuters) - Propanc Biopharma Inc PPCB.O: PROPANC BIOPHARMA’S LEAD ASSET PRP SHOWS >85% TUMOR GROWTH INHIBITION IN PRECLINICAL PANCREATIC MODELS Source text: ID:nGNXlyVpc Further company coverage: PPCB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Propanc Biopharma
See all newsNASDAQ TRADE HALT HALT NEWS PENDING AT 09:29 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition With Prp In Pancreatic Cancer Models, Contrasting Profile With Revolution Medicines’ Daraxonrasib
Brief: Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock - SEC Filing
Brief: Propanc Biopharma To File Cta In Australia For Phase 1B Study In 30–40 Advanced Cancer Patients